ALLMedicine™ Bone Marrow Failure Center

Nov 30th, 2021 - Hematopoietic stem cell transplantation (HSCT) remains the only curative treatment for a variety of hematological diseases. Allogenic HSCT requires hematopoietic stem cells (HSCs) from matched donors and comes with cytotoxicity and mortality. Rece...

Nov 26th, 2021 - Aplastic anemia (AA) is a bone marrow failure syndrome with high morbidity and mortality. Bone marrow (BM)‑mesenchymal stem cells (MSCs) are the main components of the BM microenvironment, and dysregulation of BM‑MSC adipogenic differentiation is ...

Nov 22nd, 2021 - Most acquired aplastic anemia ensues from immune-mediated destruction of hematopoietic stem and progenitor cells. Immunosuppression is the definitive treatment of patients with acquired aplastic anemia who are not candidates for immediate hematopo...

Nov 17th, 2021 - Fanconi anemia (FA) is a rare genetic disease that often presents as a bone marrow failure (BMF) syndrome but also can affect any other organ. Etiologically, loss of function mutations in more than 21 different gene members of the FA core complex ...

Nov 13th, 2021 - Human telomere biology disorders (TBD)/short telomere syndromes (STS) are heterogeneous disorders caused by inherited loss-of-function mutations in telomere-associated genes. Here, we identify three germline heterozygous missense variants in RPA1 ...

Jun 9th, 2015 - Allogeneic hematopoietic stem cell transplantation (HSCT) offers the potential to cure patients with an inherited bone marrow failure syndrome (IBMFS). However, the procedure involves the risk of treatment-related mortality and may be associated w...

Nov 22nd, 2021 - Most acquired aplastic anemia ensues from immune-mediated destruction of hematopoietic stem and progenitor cells. Immunosuppression is the definitive treatment of patients with acquired aplastic anemia who are not candidates for immediate hematopo...

Nov 17th, 2021 - Fanconi anemia (FA) is a rare genetic disease that often presents as a bone marrow failure (BMF) syndrome but also can affect any other organ. Etiologically, loss of function mutations in more than 21 different gene members of the FA core complex ...

Nov 10th, 2021 - Background: A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders. Pathogenic variant(s) in IBMFS genes are relevant to carcinogenesis in sporadic ca...

Sep 17th, 2021 - This is a single arm pilot study using TCR alpha/beta+ T cell-depleted peripheral blood stem cells (PBSC) from closely matched unrelated donors or partially matched/haploidentical related donors for hematopoietic stem cell transplant (HSCT) in pat...

Jul 12th, 2021 - Hematopoietic stem cell transplantation is the only curative choice for a number of inherited bone marrow failure syndromes, hemoglobinopathies, metabolic disorders and primary immune deficiencies. While survival of these patients is typically bet...

Oct 26th, 2021 - Prostate cancer is a highly hetero-geneous disease, with individual tumor cells having distinct genomic and pheno-typic characteristics, resulting in a great deal of variability in patients’ disease course. Although some pros-tate cancers are slow...

Oct 6th, 2021 - Ronan T. Swords, MD, PhD Pap Corps Endowed Professor in Leukemia Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami, FL Although there have been advances in therapeutics and supportive care, the...

Sep 21st, 2021 - WHAT Is Cord Blood? Umbilical cord blood remains in the placenta and umbilical cord after a baby is born. This blood is rich in stem cells, which may be able to help cure some life threatening diseases. Stem cells – also known as ‘master cells’ - ...

Apr 2nd, 2021 - Transcript: Robert J. Kreitman, MD: Hairy cell leukemia is a rare chronic B-cell leukemia that accounts for 2% of all leukemias, with approximately 1200 new cases reported in the United States each year. Major advances in the treatment and unde...

Apr 2nd, 2021 - Amy DeZern, MD, MHS: Hello, and welcome to this OncLive® Insights®, Treatment Options in Myelodysplastic Syndromes. I am Amy DeZern from Johns Hopkins University School of Medicine in Baltimore, Maryland. Joining me is Rami Komrokji from H. Lee Mo...